INSIGHTS ON CONTRACT PHARMA MANUFACTURING
-
![Scientists In Lab Working Together On Digital Tablet GettyImages-893884830]( "Transitioning From Academic Research To Drug Formulation And Development")
Transitioning From Academic Research To Drug Formulation And DevelopmentThe transition from academic research and studies to industry research demands that individuals master additional skills, sets different objectives, and defines “success” differently.
-
![Singota Solutions - SA25 Workcell]( "Advancing Aseptic Filling: Evaluating The Revolutionary SA25 Workcell")
Advancing Aseptic Filling: Evaluating The Revolutionary SA25 WorkcellExamine how leveraging a fully robotic aseptic filling system enables versatility, high yields, and low losses, as well as precise and repeatable fill parameters batch to batch.
-
![Pipette clean room laboratory cell and gene GettyImages-530817998]( "Opportunities To Accelerate Allogeneic Cell Therapy")
Opportunities To Accelerate Allogeneic Cell TherapyLearn more about the potential of allogeneic cell therapies to combine the efficacy of personalized medicine with the scalability, accessibility, and uniformity of traditional off-the-shelf therapeutics.
-
![Chromatography GettyImages-1392302602]( "Nitrosamine Impurities Deadline: Are Your Products Compliant?")
Nitrosamine Impurities Deadline: Are Your Products Compliant?The FDA nitrosamine contamination guidance set deadlines of Nov. 1, 2023, for risk assessment updates and Aug. 1, 2025, for full NDSRI limit compliance.
-
![GettyImages-1441662840-lab-team-communication-collaboration]( "The Role Of The Technical Transfer Executive Sponsor")
The Role Of The Technical Transfer Executive SponsorExplore the importance of understanding a CDMO’s flexibility and culture, models and scale of equipment, technical capabilities, regulatory support, quality system, and executive sponsorship model.
-
![23_10_OPL_Challenges_Webinar_Seg11]( "The Fundamental Outsourcing Question All Sponsors Face")
The Fundamental Outsourcing Question All Sponsors FaceTo end our Outsourced Pharma Live event on strategies for quality and regulatory outsourcing challenges, Chief Editor Louis Garguilo emphasizes the crucial question to ask when selecting a CDMO.
-
![23_10_OPL_Challenges_Webinar_Seg10]( "How To Connect Quality And Regulatory “At The Hip”")
How To Connect Quality And Regulatory “At The Hip”Our Outsourced Pharma Live panel of experts introduce challenges and strategies to ensure your internal – and external partners’ – quality and regulatory professionals work together.
-
![23_10_OPL_Challenges_Webinar_Seg09]( "File First In Europe, Then The U.S.?")
File First In Europe, Then The U.S.?Karla Knower, Global Head of Regulatory Affairs, Paradigm Biopharmaceuticals, answers a challenging question from an attendee at a recent Outsourced Pharma Live.
-
![23_10_OPL_Challenges_Webinar_Seg08]( "The Nature Of Quality Management Needs To Change")
The Nature Of Quality Management Needs To ChangeIn these 3 minutes, Bikash Chatterjee, an Outsourced Pharma Board Member, discusses how the current drug development and manufacturing landscape necessitates different approaches for quality teams.
-
![23_10_OPL_Challenges_Webinar_Seg07]( "The Wrong Way For Your CDMO To Upgrade Facilities")
The Wrong Way For Your CDMO To Upgrade FacilitiesChristine Feaster, who has worked for top 50 pharma and start-up organizations, relates a case study as a warning to sponsors when CDMOs look to upgrade facilities and add capabilities.
